PD-1/PD-L1-IN 3 TFA
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 1966.19 |
| Molecular Formula | C91H127F3N24O20S |
| SMILES | - |
Summary
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1 , with IC 50 s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases [1] .
IC50 & Target
IC50: 5.60 nM (PD-1/PD-L1); 7.04 nM (CD80/PD-L1) [1]
In Vitro
PD-1/PD-L1-IN 3 (0.1 nM-10 μM) inhibits the binding of PD-1 and CD80 to PD-L1, with IC
50
s of 5.60 nM and 7.04 nM
[1]
.
PD-1/PD-L1-IN 3 blocks the binding of recombinant PD-L1-Ig to Jurkat-PD-1 cells, and also block binding of recombinant PD-1-Ig to either L2987 or LK35.2-hPD-L1, with IC
50
s of 26 nM, 12 nM, and 3.5 nM, respectively
[1]
.
PD-1/PD-L1-IN 3 (0.001-100 μM) promotes IFN secretion by CMV-specific T cells in a dose-dependent manner, with an EC
50
of 400 nM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture and light
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
H 2 O : 50 mg/mL ( 25.43 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.5086 mL | 2.5430 mL | 5.0860 mL |
| 5 mM | 0.1017 mL | 0.5086 mL | 1.0172 mL |
| 10 mM | 0.0509 mL | 0.2543 mL | 0.5086 mL |
